These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4359954)

  • 21. Influence of detergent additives on mobility of native and subviral rhinovirus particles in capillary electrophoresis.
    Kremser L; Petsch M; Blaas D; Kenndler E
    Electrophoresis; 2006 Mar; 27(5-6):1112-21. PubMed ID: 16523456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanical stiffening of human rhinovirus by cavity-filling antiviral drugs.
    Valbuena A; Rodríguez-Huete A; Mateu MG
    Nanoscale; 2018 Jan; 10(3):1440-1452. PubMed ID: 29302674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fragmentation of RNA in virus particles of rhinovirus type 14.
    Gauntt CJ
    J Virol; 1974 Mar; 13(3):762-4. PubMed ID: 4362873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of concanavalin A on the early events of infection by rhinovirus type 2 and poliovirus type 2.
    Lonberg-Holm K
    J Gen Virol; 1975 Sep; 28(3):313-27. PubMed ID: 170375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.
    Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC
    J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on the in vitro uncoating of poliovirus. III. Roles of membrane-modifying and -stabilizing factors in the generation of subviral particles.
    De Sena J; Torian B
    Virology; 1980 Jul; 104(1):149-63. PubMed ID: 6249022
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.
    Patick AK; Binford SL; Brothers MA; Jackson RL; Ford CE; Diem MD; Maldonado F; Dragovich PS; Zhou R; Prins TJ; Fuhrman SA; Meador JW; Zalman LS; Matthews DA; Worland ST
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2444-50. PubMed ID: 10508022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-rhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivatives.
    Garozzo A; Cutrì CC; Castro A; Tempera G; Guerrera F; Sarvà MC; Geremia E
    Antiviral Res; 2000 Mar; 45(3):199-210. PubMed ID: 10771083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.
    Shepard DA; Heinz BA; Rueckert RR
    J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human rhinovirus type 16: mutant V1210A requires capsid-binding drug for assembly of pentamers to form virions during morphogenesis.
    Lee WM; Wang W
    J Virol; 2003 Jun; 77(11):6235-44. PubMed ID: 12743280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of close relationship between three strains of human rhinoviruses as determined by their RNA sequences.
    Yin FH; Lonberg-Holm K; Chan SP
    J Virol; 1973 Jul; 12(1):108-13. PubMed ID: 4126194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral effect of hyperthermic treatment in rhinovirus infection.
    Conti C; De Marco A; Mastromarino P; Tomao P; Santoro MG
    Antimicrob Agents Chemother; 1999 Apr; 43(4):822-9. PubMed ID: 10103186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.
    Patick AK; Brothers MA; Maldonado F; Binford S; Maldonado O; Fuhrman S; Petersen A; Smith GJ; Zalman LS; Burns-Naas LA; Tran JQ
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2267-75. PubMed ID: 15917520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth of human rhinovirus in H1-HeLa cell suspension culture and purification of virions.
    Lee WM; Chen Y; Wang W; Mosser A
    Methods Mol Biol; 2015; 1221():49-61. PubMed ID: 25261306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformational changes, plasma membrane penetration, and infection by human rhinovirus type 2: role of receptors and low pH.
    Brabec M; Baravalle G; Blaas D; Fuchs R
    J Virol; 2003 May; 77(9):5370-7. PubMed ID: 12692239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Separation and biospecific identification of subviral particles of human rhinovirus serotype 2 by capillary zone electrophoresis.
    Okun VM; Blaas D; Kenndler E
    Anal Chem; 1999 Oct; 71(20):4480-5. PubMed ID: 10546529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics of thermal denaturation of human rhinoviruses in the presence of anti-viral capsid binders analyzed by capillary electrophoresis.
    Okun VM; Nizet S; Blaas D; Kenndler E
    Electrophoresis; 2002 Mar; 23(6):896-902. PubMed ID: 11920874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Queensland fruit fly virus, a probable member of the Picornaviridae.
    Bashiruddin JB; Martin JL; Reinganum C
    Arch Virol; 1988; 100(1-2):61-74. PubMed ID: 3133998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-rhinovirus-specific activity of the alpha-sympathomimetic oxymetazoline.
    Koelsch S; Tschaikin M; Sacher F
    Arzneimittelforschung; 2007; 57(7):475-82. PubMed ID: 17803062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of action of the antiviral compound MDL 20,610.
    Kenny MT; Torney HL; Dulworth JK
    Antiviral Res; 1988 Jul; 9(4):249-61. PubMed ID: 2849377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.